Investigational Drug Services

Indianapolis, Indiana 46202

0 studies enrolling now · 5 studies all time

What they study most

Advanced or Recurrent Solid Tumors, Advanced, Androgen Receptor Positive Triple Negative Breast Cancer, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Breast Cancer, Breast Neoplasms, Ewing Sarcoma, Lupus Erythematosus, Systemic, Ovarian Cancer, Epithelial, Pancreas Cancer, Prostate Cancer, Small Cell Lung Carcinoma

Studies at this site

• Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer — Completed
• Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer — Completed
• A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) — Stopped early
• Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors — Completed
• Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus — Completed